Compare SCLX & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | SACH |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | 34 | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 46.9M |
| IPO Year | N/A | N/A |
| Metric | SCLX | SACH |
|---|---|---|
| Price | $6.48 | $1.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 92.4K | ★ 121.0K |
| Earning Date | 04-10-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 19.23% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $122.52 | $145.00 |
| Revenue Next Year | $186.30 | $6.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.09 | $0.80 |
| 52 Week High | $34.27 | $1.35 |
| Indicator | SCLX | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 39.05 | 44.56 |
| Support Level | $6.20 | $0.99 |
| Resistance Level | $8.18 | $1.12 |
| Average True Range (ATR) | 1.38 | 0.03 |
| MACD | -0.32 | -0.00 |
| Stochastic Oscillator | 1.16 | 12.50 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.